BiondVax Pharmaceuticals Universal Flu Vaccine Pivotal Phase 3 Study Results by End October
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ’s pivotal Phase 3 trial in Europe was completed in June 2020 and the analysis of the results are expected in the fall. The trial,…
Continue Reading
BiondVax Pharmaceuticals Universal Flu Vaccine Pivotal Phase 3 Study Results by End October